Education

Clinical Outcomes in Adults With Hemophilia B With and Without Pre-existing Neutralizing Antibodies to AAV5: 6 Month Data From the Phase 3 Etranacogene Dezaparvovec HOPE-B Gene Therapy Trial

Conference Coverage

Paul Batty, MBBS, PhD

Efficacy and Safety of Valoctocogene Roxaparvovec Adeno-associated Virus Gene Transfer for Severe Hemophilia A: Results From the Phase 3 GENEr8-1 Trial

Conference Coverage

Paul Batty, MBBS, PhD

Liver Safety Case Report From the Phase 3 HOPE-B Gene Therapy Trial in Adults With Hemophilia B

Conference Coverage

Paul Batty, MBBS, PhD

Investigation of Early Outcomes Following Adeno-associated Viral Gene Therapy in a Canine Hemophilia Model

Conference Coverage

Paul Batty, MBBS, PhD

Evolution of AAV Vector Gene Therapy Is Ongoing in Hemophilia. Will the Unique Features of BAY 2599023 Address the Outstanding Needs?

Conference Coverage

Paul Batty, MBBS, PhD

52 Week Efficacy and Safety of Etranacogene Dezaparvovec in Adults With Severe or Moderate-severe Hemophilia B: Data From the Phase 3 HOPE-B Gene Therapy Trial

Conference Coverage

Paul Batty, MBBS, PhD

Train-the-Trainer Toolkit

Toolkit

Gene Therapy in Hemophilia: An APSTH ISTH Sponsored Symposium

2020 Virtual Learning Sessions

Presented by Pantep Angchaisuksiri, MD, Flora Peyvandi, MD, PhD, Steven W. Pipe, MD, and Alok Srivastava, MD, FRACP, FRCPA, FRCP

Hemophilia Gene Therapy-Key Components of Clinical Care

2020 Virtual Learning Sessions

Presented by Michael Makris, MA, MB BS, MD, FRCP, FRCPath, Wolfgang Miesbach, MD, PhD, Flora Peyvandi, MD, PhD

Follow-up on a Novel Adeno-Associated Virus (AAV) Gene Therapy (FLT180a) Achieving Normal FIX Activity Levels in Severe Hemophilia B (HB) Patients (B-AMAZE Study)

Conference Coverage

Pratima Chowdary, MRCP, FRCPath

Characterisation of Adeno-Associated Virus Vector Persistence After Long-Term Follow-up in the Haemophilia A Dog Model

Conference Coverage

Paul Batty, MBBS, PhD

Efficacy and Safety of Etranacogene Dezaparvovec in Adults With Severe or Moderate-severe Hemophilia B: First Data From the Phase 3 Hope-B Gene Therapy Trial

Conference Coverage

Steven W. Pipe, MD

Etranacogene Dezaparvovec (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults With Severe or Moderate-Severe Hemophilia B

Conference Coverage

Annette von Drygalski, MD, PharmD

Long-term Outcomes: Durability and Safety

Interactive Webinars

Presented by Prof. Margareth C. Ozelo, MD, PhD

Key Considerations: Advances in Gene Therapy for Hemophilia ENDURING

2020 Virtual Learning Sessions

Presented by Glenn Pierce, MD, PhD, Lindsey George, MD, Alfonso Iorio, MD, Barbara Konkle, MD

EAHAD Gene Therapy Working Group

Podcasts

Presented by Wolfgang Miesbach, MD

ISTH Gene Therapy for Hemophilia Initiative and the Role of EAHAD

Podcasts

Presented by Flora Peyvandi, MD, PhD

History of EAHAD and the Upcoming Congress

Podcasts

Presented by Aislin Ryan, the CEO of EAHAD

Hemophilia Gene Therapy: Expectations for Reliability and Accessibility

Podcasts

Presented by Andrew Leavitt, MD

First-in-Human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A – BAY 2599023 has Broad Patient Eligibility and Stable and Sustained Long-Term Expression of FVIII

Conference Coverage

Steven W. Pipe, MD

Etranacogene Dezaparvovec (AAV5-Padua hFIX variant), an Enhanced Vector for Gene Transfer in Adults With Severe or Moderate-Severe Hemophilia B: Two Year Data From a Phase 2b Trial

Conference Coverage

Steven W. Pipe, MD 

First Data From the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults With Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing

Conference Coverage

Steven W. Pipe, MD

AMT-060 Gene Therapy in Adults With Severe or Moderate-Severe Hemophilia B Confirm Stable FIX Expression and Durable Reductions in Bleeding and Factor IX Consumption for Up to 5 Years

Conference Coverage

Wolfgang A. Miesbach, MD

Updated Follow-up of the Alta Study, a Phase 1/2 Study of Giroctocogene Fitelparvovec (SB-525) Gene Therapy in Adults With Severe Hemophilia

Conference Coverage

Barbara A. Konkle, MD

Subcategories

Interactive Webinars

Toolkit